Yuenyongviwat Varah, Kitjakrancharoensin Peranut, Anusitviwat Chirathit, Iamthanaporn Khanin
Department of Orthopedics, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
Orthop Rev (Pavia). 2025 Aug 20;17:143092. doi: 10.52965/001c.143092. eCollection 2025.
Effective management of postoperative pain is essential for promoting recovery and improving overall patient outcomes after total knee arthroplasty (TKA). Intravenous corticosteroids, especially dexamethasone, have become increasingly popular due to their strong anti-inflammatory effects, which can enhance pain control while minimizing side effects. However, the optimal dosing strategy for dexamethasone remains unclear, as most studies have primarily focused on fixed high doses.
This retrospective case-matched study aimed to evaluate the effectiveness of weight-based low-dose intravenous dexamethasone (0.1 mg/kg) in managing postoperative pain following TKA.
Patients who underwent unilateral TKA for primary osteoarthritis were retrospectively analyzed and divided into two cohorts based on the timing of their surgery. The control group, consisting of patients who underwent TKA between March 2019 and November 2020, did not receive dexamethasone. In contrast, patients operated on between December 2020 and May 2022 received a preoperative weight-based dose of 0.1 mg/kg intravenous dexamethasone. Postoperative pain was assessed using the Verbal Numerical Rating Scale (VNRS), and fentanyl consumption was recorded over the first 72 hours postoperatively.
The dexamethasone group demonstrated significantly lower pain scores at all measured intervals up to 60 hours postoperatively (p < 0.05) compared to the control group. Additionally, patients receiving dexamethasone required significantly less fentanyl in the first 24 hours and had lower cumulative fentanyl consumption over the entire 72-hour postoperative period (p < 0.001). There were no significant differences between the two groups in terms of hospital stay, deep infection rates, or other complications.
Weight-based low-dose dexamethasone (0.1 mg/kg) appears to be an effective strategy for reducing postoperative pain and opioid use following TKA.
有效的术后疼痛管理对于促进全膝关节置换术(TKA)后的恢复和改善患者总体预后至关重要。静脉注射皮质类固醇,尤其是地塞米松,因其强大的抗炎作用而越来越受欢迎,这种作用可以增强疼痛控制,同时将副作用降至最低。然而,地塞米松的最佳给药策略仍不明确,因为大多数研究主要集中在固定高剂量上。
这项回顾性病例匹配研究旨在评估基于体重的低剂量静脉注射地塞米松(0.1mg/kg)在TKA术后疼痛管理中的有效性。
对因原发性骨关节炎接受单侧TKA的患者进行回顾性分析,并根据手术时间分为两个队列。对照组由2019年3月至2020年11月接受TKA的患者组成,未接受地塞米松治疗。相比之下,2020年12月至2022年5月接受手术的患者术前接受了基于体重的0.1mg/kg静脉注射地塞米松。使用言语数字评定量表(VNRS)评估术后疼痛,并记录术后前72小时的芬太尼消耗量。
与对照组相比,地塞米松组在术后60小时内的所有测量时间点疼痛评分均显著更低(p<0.05)。此外,接受地塞米松治疗的患者在术后前24小时所需的芬太尼显著更少,并且在术后整个72小时期间的累积芬太尼消耗量更低(p<0.001)。两组在住院时间、深部感染率或其他并发症方面无显著差异。
基于体重的低剂量地塞米松(0.1mg/kg)似乎是减少TKA术后疼痛和阿片类药物使用的有效策略。